Observational studyOrphanet journal of rare diseases2025

Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation.

Antonio Toscano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.